[HTML][HTML] Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

PC Iyer, R Dadu, M Gule-Monroe, NL Busaidy… - … for immunotherapy of …, 2018 - Springer
Background Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer.
Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC, …

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma

…, NL Busaidy, C Lu, S Ahmed, MK Gule-Monroe… - Thyroid, 2019 - liebertpub.com
Background: When achieved, complete surgical resection improves outcomes in anaplastic
thyroid carcinoma (ATC). However, most ATC patients present with advanced inoperable …

Computer-aided detection of brain metastases in T1-weighted MRI for stereotactic radiosurgery using deep learning single-shot detectors

Z Zhou, JW Sanders, JM Johnson, MK Gule-Monroe… - Radiology, 2020 - pubs.rsna.org
Background Brain metastases are manually identified during stereotactic radiosurgery (SRS)
treatment planning, which is time consuming and potentially challenging. Purpose To …

Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases

…, M Hughes, AS Raghavendra, M Gule-Monroe… - Clinical Cancer …, 2023 - AACR
… Lascola, M. Gule-Monroe). CNS responses were recorded according to modified response
assessment in neuro-oncology brain metastases (RANO-BM) criteria and reported for the …

Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma

…, M Zafereo, N Gross, KR Hess, M Gule-Monroe… - Thyroid, 2018 - liebertpub.com
Background: Patients with anaplastic thyroid cancer (ATC) have a dismal prognosis, despite
systemic cytotoxic chemotherapy. The objective of this study was to investigate the efficacy …

Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors

…, A Ying, M Gule-Monroe, JR Wang, M Zafereo… - Thyroid, 2020 - liebertpub.com
Background: The BRAF V600E mutation is the most common driver mutation in papillary
thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered …

Neoadjuvant selpercatinib for advanced medullary thyroid cancer

…, M Zafereo, MD Williams, MK GuleMonroe… - Head & …, 2021 - Wiley Online Library
Background Targeted kinase inhibitors have been increasingly utilized in the treatment of
advanced medullary thyroid cancer (MTC) over the last decade. Recently, highly potent next …

MetNet: Computer-aided segmentation of brain metastases in post-contrast T1-weighted magnetic resonance imaging

…, JM Johnson, M Gule-Monroe, M Chen… - Radiotherapy and …, 2020 - Elsevier
Purpose Brain metastases are manually contoured during stereotactic radiosurgery (SRS)
treatment planning, which is time-consuming, potentially challenging, and laborious. The …

Neoadjuvant selective RET inhibitor for medullary thyroid cancer: A case series

KJ Contrera, MK Gule-Monroe, MI Hu, ME Cabanillas… - Thyroid, 2023 - liebertpub.com
Materials and Methods This retrospective consecutive case series was conducted under
institutional IRB protocol PA-14-1082, by which patient consent was waived. All patients with …

Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC).

…, S Liu, BM Fellman, ND Gross, M Gule-Monroe… - 2020 - ascopubs.org
6514 Background: ATC is a rare/aggressive cancer with dismal outcome. Dabrafenib/trametinib
is approved for BRAF-mutated ATC but pts eventually develop resistance. There are no …